Overview
GLP-3 (R) is a synthetic 39-amino-acid peptide analog modified with a C20 fatty diacid chain. It acts as a triple agonist at the GLP-1, GIP, and glucagon receptors and is widely used in laboratory and preclinical research as a model compound to investigate energy balance, glucose homeostasis, lipid metabolism, and related signaling pathways in various in vitro and animal model systems.
Research Applications (Observational Data from Published Studies) The following points summarize observations reported in scientific literature from preclinical (in vitro/animal) and human clinical trials and are provided solely for informational and research-planning purposes:
- Weight Regulation Research: In diet-induced obese rodent models, non-human primates, and Phase 2/3 human clinical trials, GLP-3 (R) administration has produced profound body-weight reduction (up to -24.2% mean weight loss at 12 mg dose after 48 weeks in adults with obesity) primarily through decreased energy intake and markedly increased energy expenditure via glucagon receptor-mediated effects.
- Glucose Homeostasis Models: In diabetic and obese animal models as well as Phase 2/3 human trials in patients with type 2 diabetes, GLP-3 (R) has significantly improved glucose tolerance, lowered fasting glucose, reduced HbA1c by up to -2.02% (12 mg dose), and enhanced insulin sensitivity while suppressing hepatic glucose production.
- Lipid Metabolism Studies: In preclinical dyslipidemia models and human Phase 2 trials, GLP-3 (R) has consistently lowered circulating triglycerides (by ~30–50%), total cholesterol, LDL-cholesterol, and non-HDL cholesterol while favorably shifting overall lipid profiles.
- Liver Fat Accumulation Research: In rodent models of MASLD/NAFLD and a dedicated Phase 2 human substudy, GLP-3 (R) has markedly reduced hepatic steatosis and liver fat content (>80–85% relative reduction in MRI-PDFF at higher doses), together with improvements in liver inflammation and fibrosis markers.
Important Legal Disclaimer For laboratory research use only. Not for human or veterinary use. Not for diagnostic, therapeutic, cosmetic, or food purposes. Not approved by the FDA or any regulatory agency. Researchers are responsible for compliance with all applicable laws and institutional guidelines.
Chemical Information
- Sequence: Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Leu-Leu-Asp-Lys-Lys[(C20 diacid-γGlu-Aoc)]-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
- Common Name: LY3437943, GLP-3 (R)
- Molecular Formula: C₂₂₃H₃₄₃N₄₇O₇₀ (approximate, lipidated form)
- Molecular Weight: ~4731–4845 g/mol (commonly reported 4731.41 g/mol)
- CAS Number: 2381089-83-2
- PubChem CID: 171390338
Loading...